语言

China

中国 地图

查看印度查看巴西

省份

请在下方的农业企业信息库中进行搜索

行业

位置: 中国 - Shanghai - 行业- - ANTENGENE

  • 公司名称: ANTENGENE

  • 联系人:

  • 电话:

  • 行业: 实验室 Laboratory

  • 地址: Suite 1209-1209, Block B, Zhongshan SOHO Plaza 1065 West Zhongshan Road Changning District, Shanghai, Shanghai, 200051 China

  • E-mail:

  • Company category:

  • 员工数量:

  • 网站地址:

  • Last updated: 2026-03-23

纳税人编号:

营收:

公司介绍 ：

Antengene is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative first-in-class/best-in-class therapeutics for cancer patients. We are currently seeking global partnerships for our differentiating cancer and autoimmune programs, as well as AnTenGager™, the second-generation T cell platform (2+1 structure with masking technology) we developed. For the AnTenGager™ TCE platform, we are open to partnership opportunities at the program and platform level to develop novel T-cell engagers (TCEs) for autoimmune diseases, etc. For platform collaborations, we welcome partners to bring their own DAA/antibody to integrate into AnTenGager™, or to just nominate targets for us to do (early) development of bi- or trispecific TCE programs. AnTenGager™ TCE platform - “2+1” structure facilitates bivalent binding to the targets, enabling the detection and depletion of cells with low expression of the targets - “Steric hindrance” allows unique TAA-dependent CD3 binding and activation, which mitigates the risk of off-target CRS - Masking is achieved through the low stiffness of the CD3 arm, which is NOT protease-dependent, does NOT rely on the tumor microenvironment (TME) to be effective, and functions effectively in both cancer and non-cancer disease settings - In-house developed proprietary CD3 sequences (diverse affinities) with fast on/fast off kinetics and targeting a unique conformational epitope on CD3 that expressed on T-cells, which mitigates risk of on-target CRS Good PK profile and developability; PCT filed Lead program is ATG-201 (CD19xCD3): specifically designed for autoimmune diseases - Preclinical studies have shown it delivers superior efficacy with a reduced risk of cytokine release syndrome compared to current clinical benchmarks (thanks to the steric hindrance of the CD3 arm in our TCE structure) >> Head-to-head studies against CLN-978 and blinatumomab show that ATG-201 offers comparable or better naïve B cell depletion and reduced cytokine release >> In another in vivo study, a single dose of ATG-201 shows better efficacy compared to CN201 – ATG-201 completely depletes B cells in CD34 humanized mice, with no detectable B cells in blood, bone marrow, or spleen 14 days post-treatment - Good stability at high concentration (125mg/mL) and suitable for potential SC formulation development - NHP pilot tox data expected in Q2 2025; GLP will initiate in Q2 2025; Plan to submit an IND application by Q4 2025 Novel targets for oncology ATG-106 (CDH6 x CD3): ovarian cancer & RCC ATG-110 (LY6G6D x CD3): MSS CRC ATG-107 (FLT3 x CD3): AML ATG-021 (GPRC5D x CD3): MM ATG-102 (LILRB4 x CD3): AML/CMML ATG-112 (ALPPL2 x CD3): Gynecological Tumors & Lung Cancer Undisclosed novel target: HCC

公司产品：